Karman is undervalued despite best-in-class revenue and EBITDA growth, trading at a discount to high-growth A&D peers. KRMN's robust 2026 guidance, strong Q1 results, and high revenue visibility underpin confidence in continued rapid compounding. Recent catalysts include munitions acceleration agreements, a growing Space and Launch pipeline, and a significant $250M contract pending.